Impact BioMedical Inc.
IBO
$0.45
-$0.0225-4.76%
AMEX
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -13.87% | -17.80% | |||
| Depreciation & Amortization | 1.43% | -0.71% | |||
| Other Operating Expenses | 1.77% | 151.11% | |||
| Total Operating Expenses | 15.43% | -22.36% | |||
| Operating Income | -15.43% | 22.36% | |||
| Income Before Tax | 95.28% | -739.00% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 95.29% | -739.78% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -56.00% | 316.67% | |||
| Net Income | 95.33% | -738.29% | |||
| EBIT | -15.43% | 22.36% | |||
| EBITDA | -15.58% | 22.40% | |||
| EPS Basic | 95.54% | -737.95% | |||
| Normalized Basic EPS | 29.41% | -140.06% | |||
| EPS Diluted | 95.33% | -4,025.50% | |||
| Normalized Diluted EPS | 29.41% | -350.68% | |||
| Average Basic Shares Outstanding | 4.81% | 0.05% | |||
| Average Diluted Shares Outstanding | 4.81% | -84.01% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||